Neurochemical biomarkers to study CNS effects of COVID‐19: A narrative review and synthesis
Open Access
- 20 August 2021
- journal article
- review article
- Published by Wiley in Journal of Neurochemistry
- Vol. 159 (1), 61-77
- https://doi.org/10.1111/jnc.15459
Abstract
Neurological symptoms are frequently reported in patients suffering from COVID-19. Common CNS-related symptoms include anosmia, caused by viral interaction with either neurons or supporting cells in nasal olfactory tissues. Diffuse encephalopathy is the most common sign of CNS dysfunction, which likely results from the CNS consequences of the systemic inflammatory syndrome associated with severe COVID-19. Additionally, microvascular injuries and thromboembolic events likely contribute to the neurologic impact of acute COVID-19. These observations are supported by evidence of CNS immune activation in cerebrospinal fluid (CSF) and in autopsy tissue, along with detection of microvascular injuries in both pathological and neuroimaging studies. The frequent occurrence of thromboembolic events in patients with COVID-19 has generated different hypotheses, among which viral interaction with perivascular cells is particularly attractive, yet unproven. A distinguishing feature of CSF findings in SARS-CoV-2 infection is that clinical signs characteristic of neurotropic viral infections (CSF pleocytosis and blood brain barrier injury) are mild or absent. Moreover, virus detection in CSF is rare, and often of uncertain significance. In this review, we provide an overview of the neurological impact that occur in the acute phase of COVID-19, and the role of CSF biomarkers in the clinical management and research to better treat and understand the disease. In addition to aiding as diagnostic and prognostic tools during acute infection, the use of comprehensive and well characterized CSF and blood biomarkers will be vital in understanding the potential impact on the CNS in the rapidly increasing number of individuals recovering from COVID-19.Keywords
Funding Information
- Vetenskapsrådet (2018‐02532)
- Hjärnfonden (FO2019‐0228)
- Science for Life Laboratory (KAW 2020.0182)
- Stiftelsen för Gamla Tjänarinnor
- UK Dementia Research Institute
This publication has 150 references indexed in Scilit:
- CSF-Biomarkers in Olympic Boxing: Diagnosis and Effects of Repetitive Head TraumaPLOS ONE, 2012
- Biomarker-based dissection of neurodegenerative diseasesProgress in Neurobiology, 2011
- Cerebrospinal fluid and plasma biomarkers in Alzheimer diseaseNature Reviews Neurology, 2010
- In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseasesJournal of Neuroinflammation, 2010
- Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infectionAIDS Research and Therapy, 2010
- Virus and Antibody Dynamics in Acute West Nile Virus InfectionThe Journal of Infectious Diseases, 2008
- Transcriptional Regulation of CHI3L1, a Marker Gene for Late Stages of Macrophage DifferentiationOnline Journal of Public Health Informatics, 2003
- Pericyte Loss and Microaneurysm Formation in PDGF-B-Deficient MiceScience, 1997
- Diagnosis of Herpes Simplex Encephalitis: Application of Polymerase Chain Reaction to Cerebrospinal Fluid from Brain-Biopsied Patients and Correlation with DiseaseThe Journal of Infectious Diseases, 1995
- Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.The Journal of Experimental Medicine, 1984